Why the study?
Does cardiac contractility modulation improve outcomes in patients with heart failure?
Does cardiac contractility modulation improve outcomes in patients with heart failure?
Cardiac contractility modulation represents a promising novel electrical therapy for heart failure, though further research is needed to clarify its mechanisms and resolve existing controversies.
CCM shows promise in HF but mechanisms remain unclear; leaves open need for mechanistic and outcome trials before practice change.
Despite advances in our understanding of the pathology of heart failure modern conventional pharmacological therapies have proved insufficient. The application of electrical impulses during the refractory period of the cardiac contractile cycle, so-called cardiac contractility modulation (CCM), presents a new therapeutic approach with promising results demonstrated in clinical trials to date. The mechanism by which CCM exerts its effects remains inconclusive with conflicting reports. This article provides a concise review of the experimental and clinical CCM studies conducted to date with particular focus on areas of controversy and unexplored avenues of interest with this novel electrical therapy.
No takes yet. Share an insight, caveat, or question.
Winter et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: